XTX Topco Ltd Makes New $557,000 Investment in LivaNova PLC (NASDAQ:LIVN)

XTX Topco Ltd purchased a new stake in LivaNova PLC (NASDAQ:LIVN - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 14,189 shares of the company's stock, valued at approximately $557,000.

Other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of LivaNova by 2,299.7% during the 1st quarter. GAMMA Investing LLC now owns 8,759 shares of the company's stock worth $344,000 after purchasing an additional 8,394 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in LivaNova during the fourth quarter worth approximately $2,772,000. Envestnet Asset Management Inc. grew its stake in LivaNova by 15.4% in the 4th quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock worth $2,034,000 after acquiring an additional 5,850 shares during the period. Schonfeld Strategic Advisors LLC raised its holdings in LivaNova by 147.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 98,940 shares of the company's stock valued at $4,582,000 after acquiring an additional 58,911 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its stake in shares of LivaNova by 148.5% during the 4th quarter. Two Sigma Advisers LP now owns 214,545 shares of the company's stock worth $9,936,000 after purchasing an additional 128,200 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Price Performance

Shares of LIVN stock traded up $1.16 during trading hours on Thursday, hitting $48.52. The company had a trading volume of 942,871 shares, compared to its average volume of 749,373. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $57.35. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.29. The firm's fifty day moving average is $44.72 and its 200 day moving average is $42.82. The firm has a market capitalization of $2.65 billion, a price-to-earnings ratio of -12.47 and a beta of 0.92.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.21. The firm had revenue of $352.50 million for the quarter, compared to analysts' expectations of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The company's quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.93 earnings per share. On average, sell-side analysts predict that LivaNova PLC will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on LIVN. Barclays reduced their target price on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a report on Thursday, May 8th. Wall Street Zen lowered LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. Needham & Company LLC reiterated a "buy" rating and issued a $64.00 price target on shares of LivaNova in a research note on Tuesday, May 13th. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price on the stock in a report on Tuesday, May 20th. Finally, Robert W. Baird raised their price target on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $59.29.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.